Vertex Pharmaceuticals
VRTX
644 hedge funds and large institutions have $35.9B invested in Vertex Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 99 funds opening new positions, 260 increasing their positions, 205 reducing their positions, and 60 closing their positions.
65% more first-time investments, than exits
New positions opened: 99 | Existing positions closed: 60
27% more repeat investments, than reductions
Existing positions increased: 260 | Existing positions reduced: 205
5% more funds holding
Funds holding: 611 → 644 (+33)
0.48% more ownership
Funds ownership: 94.3% → 94.78% (+0.48%)
1% less capital invested
Capital invested by funds: $36.1B → $35.9B (-$204M)
9% less call options, than puts
Call options by funds: $206M | Put options by funds: $225M
23% less funds holding in top 10
Funds holding in top 10: 13 → 10 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$275M |
| 2 |
Renaissance Technologies
New York
|
+$219M |
| 3 |
HM
HealthCor Management
New York
|
+$102M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
+$91.6M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$85.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$840M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$131M |
| 3 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$110M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$109M |
| 5 |
Jennison Associates
New York
|
-$71.1M |
VRTX Hedge Fund Activity: Q4 2017 in Review
644 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q4 2017, worth a combined $35.9B — down 0.56% from $36.1B a quarter earlier.
Buyers outnumbered sellers: 99 funds opened new VRTX positions and 60 closed out — a net gain of 39 holders — while 260 added to existing stakes and 205 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $275M. The largest seller was Capital World Investors, cutting an estimated $840M.
- 644 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q4 2017, up from 611 in Q3 2017.
- Funds reported $35.9B of Vertex Pharmaceuticals stock for Q4 2017, down 0.56% quarter-over-quarter.
- 99 funds opened new Vertex Pharmaceuticals positions in Q4 2017 and 60 closed out, a net change of +39 holders.
- The largest Vertex Pharmaceuticals buyer in Q4 2017 was T. Rowe Price Associates, an estimated $275M added.
- The largest Vertex Pharmaceuticals seller in Q4 2017 was Capital World Investors, an estimated $840M sold.
Based on aggregated 13F filings for Q4 2017.